Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TenNor Announces Positive Results from US Trial of Novel Anti-bacterial

publication date: Nov 12, 2019

TenNor Therapeutics of Suzhou announced positive top-line results for its anti-bacterial treatment from a US Phase II trial conducted in patients with acute bacterial skin and skin structure infection. After 48-72 hours, TNP-2092 produced a response rate of 76.3% compared to 67.5% for vancomycin. TNP-2092 is a first-in-class drug conjugate that inhibits three drug targets: RNA polymerase, DNAgyrase and topoisomerase IV. TenNor is developing the candidate as a treatment for bacterial biofilm infections associated with implanted medical devices. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital